In this clinical study, heroin addicts were randomized into separate treatment groups of placebo, 40 mg/day MN-166 or 80 mg/day MN-166. Safety and tolerability and preliminary efficacy were major analyzed outcomes. Dose-related ibudilast efficacy was also observed in the study. For example, physical withdrawal symptoms were significantly reduced (p≤0.05) by MN-166 treatment as measured by the Subjective Opioid Withdrawal Scale (SOWS) and oxycodone-mediated analgesia (McGill pain questionnaire) was significantly enhanced (p≤0.05) by 80 mg/day ibudilast compared to placebo. Moreover, opioid-related pupil constriction was greater in the 80 mg/day ibudilast group compared to the placebo group (p≤0.05) suggesting lessened tolerance development. Ibudilast was safe and well-tolerated in the study with no serious adverse events, no discontinuations due to treatment and no impact on opioid respiratory changes compared to placebo.
"We are pleased with the outcome of this study and excited that it was selected for presentation at AAN," commented Dr. Yuichi Iwaki, President and CEO of MediciNova. "We look forward to the next milestone in this indication which will be completion of the ongoing Phase 2a clinical trial of MN-166 in subjects addicted to prescription opioids or heroin."
About the Study
The trial was led by Sandra Comer, Ph.D., Professor of Clinical Neurobiology, and additional drug addiction researchers, including Ziva Cooper, Ph.D., Assistant Professor of Clinical Neurobiology at Columbia. The 21-day, inpatient, double-blind, placebo-controlled study enrolled 30 non-treatment-seeking, heroin-dependent volunteers who were maintained on oral morphine for the first 14 days. In the first week, all subjects received placebo and on day 8, participants were randomized to continue placebo (P), low dose (L; 20 mg twice daily (40 mg/day)) ibudilast, or high dose (H; 40 mg twice daily (80 mg/day)) ibudilast. Data were analyzed from 10 subjects completing each treatment arm. In the third week, morphine was no longer administered so that withdrawal phenomena during detoxification could be monitored.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV